SK62593A3 - Method of constructing synthetic leader sequences - Google Patents

Method of constructing synthetic leader sequences Download PDF

Info

Publication number
SK62593A3
SK62593A3 SK62593A SK62593A SK62593A3 SK 62593 A3 SK62593 A3 SK 62593A3 SK 62593 A SK62593 A SK 62593A SK 62593 A SK62593 A SK 62593A SK 62593 A3 SK62593 A3 SK 62593A3
Authority
SK
Slovakia
Prior art keywords
sequence encoding
dna sequence
amino acids
yeast
dna
Prior art date
Application number
SK62593A
Other languages
English (en)
Slovak (sk)
Inventor
Lars Christiansen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of SK62593A3 publication Critical patent/SK62593A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Consolidation Of Soil By Introduction Of Solidifying Substances Into Soil (AREA)
SK62593A 1990-12-19 1991-12-18 Method of constructing synthetic leader sequences SK62593A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK300090A DK300090D0 (da) 1990-12-19 1990-12-19 Fremgangsmaade til fremstilling af leadersekvenser
PCT/DK1991/000396 WO1992011378A1 (en) 1990-12-19 1991-12-18 A method of constructing synthetic leader sequences

Publications (1)

Publication Number Publication Date
SK62593A3 true SK62593A3 (en) 1993-10-06

Family

ID=8118017

Family Applications (1)

Application Number Title Priority Date Filing Date
SK62593A SK62593A3 (en) 1990-12-19 1991-12-18 Method of constructing synthetic leader sequences

Country Status (17)

Country Link
EP (1) EP0563175A1 (ja)
JP (1) JPH06503957A (ja)
KR (1) KR930703450A (ja)
AU (1) AU660161B2 (ja)
CA (1) CA2098731A1 (ja)
CZ (1) CZ119293A3 (ja)
DK (1) DK300090D0 (ja)
FI (1) FI932831A0 (ja)
HU (1) HUT68751A (ja)
IE (1) IE914433A1 (ja)
IL (1) IL100408A0 (ja)
MX (1) MX9102684A (ja)
NZ (1) NZ241011A (ja)
PT (1) PT99848A (ja)
SK (1) SK62593A3 (ja)
WO (1) WO1992011378A1 (ja)
ZA (1) ZA919932B (ja)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI92601C (fi) * 1992-03-11 1994-12-12 Marja Makarow Menetelmä hyötyproteiinien erittämiseksi hiivoista
US5538863A (en) * 1993-07-01 1996-07-23 Immunex Corporation Expression system comprising mutant yeast strain and expression vector encoding synthetic signal peptide
US5639642A (en) * 1994-06-16 1997-06-17 Novo Nordisk A/S Synthetic leader peptide sequences
IL114160A (en) * 1994-06-17 2006-12-31 Novo Nordisk As Dna constructs encoding heterologous proteins and processes for the heterologous protein production in yeast
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
HRP940432B1 (en) * 1994-08-05 2003-10-31 Pliva Pharm & Chem Works Dna sequences encoding biosynthetic insulin precursors and process for preparation of insulin
CN102080070B (zh) 1995-03-17 2016-01-20 诺沃奇梅兹有限公司 新的内切葡聚糖酶
DK1975177T3 (da) 1996-03-01 2011-07-25 Novo Nordisk As Appetitundertrykkende peptid, formuleringer dermed og anvendelse deraf
EP1365028B1 (en) 1996-12-13 2009-03-18 Novartis Vaccines and Diagnostics, Inc. Method for expression of PDGF or IGF proteins in yeast
KR20010034305A (ko) 1998-01-23 2001-04-25 한센 핀 베네드 효모에서 원하는 폴리펩티드를 만드는 방법
CN1415019A (zh) 1999-12-29 2003-04-30 诺沃挪第克公司 用于生产在酵母中具有改进发酵产量的胰岛素前体和胰岛素前体类似物的方法
AT410217B (de) * 2000-06-15 2003-03-25 Cistem Biotechnologies Gmbh Vektor und ein verfahren zur expression und selektion randomisierter peptid-sequenzen
BR0208203A (pt) 2001-03-22 2005-04-19 Novo Nordisk Healthcare Ag Polipeptìdeo do fator vii, derivado do fator vii, composição, composição farmacêutica, construção de polinucleotìdeo, célula hospedeira eucariótica, animal transgênico, planta transgênica, e, métodos para produzir o polipeptìdeo do fator vii e um derivado do fator vii, uso de um derivado do fator vii, métodos para o tratamento de episódios de hemorragia ou distúrbios de hemorragia em um paciente ou para a intensificação do sistema hemostático normal e para inibir a formação de trobo em um paciente
WO2003027147A2 (en) 2001-09-27 2003-04-03 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
CN101870729A (zh) 2003-09-09 2010-10-27 诺和诺德医疗保健公司 凝固因子ⅶ多肽
JP2007532096A (ja) 2003-11-14 2007-11-15 ノボ　ノルディスク　アクティーゼルスカブ アシル化されたインスリンの製造方法
CN102816228A (zh) 2003-12-03 2012-12-12 诺和诺德公司 单链胰岛素
WO2005078116A1 (fr) * 2004-01-16 2005-08-25 Qiuyun Liu Methode permettant d'isoler de peptides antibacteriens et peptides isoles
JP2008538290A (ja) 2005-04-18 2008-10-23 ノボ ノルディスク アクティーゼルスカブ Ｉｌ−２１変異体
WO2007020256A1 (en) 2005-08-16 2007-02-22 Novo Nordisk A/S Method for making mature insulin polypeptides
EP2316930A1 (en) 2005-09-14 2011-05-04 Novo Nordisk Health Care AG Human coagulation factor VII polypeptides
US8722620B2 (en) 2006-02-27 2014-05-13 Novo Nordisk A/S Insulin derivatives
JP5503968B2 (ja) 2006-09-27 2014-05-28 ノボ・ノルデイスク・エー／エス 成熟インスリンポリペプチドの作製方法
ES2558930T3 (es) 2007-08-13 2016-02-09 Novo Nordisk A/S Análogos de la insulina de acción rápida
EP2178912B1 (en) 2007-08-15 2015-07-08 Novo Nordisk A/S Insulin analogues with an acyl and aklylene glycol moiety
ES2526924T3 (es) 2007-08-15 2015-01-16 Novo Nordisk A/S Insulinas con una fracción acilo que comprende unidades repetitivas de aminoácidos que contienen alquilenglicol
WO2010103038A1 (en) 2009-03-11 2010-09-16 Novo Nordisk A/S Interleukin-21 variants having antagonistic binding to the il-21 receptor
KR101870378B1 (ko) 2009-07-17 2018-06-25 릭스하스피탈렛 보체 활성화의 억제제로서의 ｍａｓｐ 이소형
CN102639559B (zh) 2009-11-25 2015-04-29 诺沃—诺迪斯克有限公司 用于制备多肽的方法
ES2583259T3 (es) 2009-12-01 2016-09-20 Novo Nordisk A/S Nuevas liasas alfa-amidantes de peptidil alfa-hidroxiglicina
CN102791730A (zh) 2010-01-22 2012-11-21 诺沃—诺迪斯克有限公司 低度o-糖基化的fgf21的制备方法
EP3815708A1 (en) 2010-03-05 2021-05-05 Omeros Corporation Chimeric inhibitor molecules of complement activation
EP2598527A4 (en) * 2010-07-28 2014-01-08 Smartcells Inc RECOMBINANT EXPRESSED INSULIN POLYPEPTIDES AND APPLICATIONS THEREOF
BR112014018630A2 (pt) 2012-02-09 2017-07-04 Var2 Pharmaceuticals Aps alvejamento de glicanos de sulfato de condroitina
US20150307865A1 (en) 2012-10-15 2015-10-29 Novo Nordisk Health Care Ag Coagulation factor vii polypeptides
JP2016521701A (ja) 2013-06-07 2016-07-25 ノヴォ ノルディスク アー／エス 成熟インスリンポリペプチドを作製するための方法
US20160376330A1 (en) 2014-02-28 2016-12-29 Novo Nordisk A/S Mating factor alpha pro-peptide variants
EP3821244A1 (en) 2018-07-13 2021-05-19 Varct Diagnostics ApS Isolation of circulating cells of fetal origin using recombinant malaria protein var2csa

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK463887D0 (da) * 1987-09-07 1987-09-07 Novo Industri As Gaerleader
CA1340772C (en) * 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
EP0387319B1 (en) * 1988-07-23 1996-03-06 Delta Biotechnology Limited Secretory leader sequences
DK105489D0 (da) * 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid

Also Published As

Publication number Publication date
ZA919932B (en) 1992-08-26
NZ241011A (en) 1993-04-28
MX9102684A (es) 1992-06-01
JPH06503957A (ja) 1994-05-12
CZ119293A3 (en) 1994-02-16
IL100408A0 (en) 1992-09-06
PT99848A (pt) 1993-06-30
AU9134891A (en) 1992-07-22
WO1992011378A1 (en) 1992-07-09
HUT68751A (en) 1995-07-28
DK300090D0 (da) 1990-12-19
AU660161B2 (en) 1995-06-15
IE914433A1 (en) 1992-07-01
FI932831A (fi) 1993-06-18
KR930703450A (ko) 1993-11-30
FI932831A0 (fi) 1993-06-18
HU9301801D0 (en) 1993-10-28
EP0563175A1 (en) 1993-10-06
CA2098731A1 (en) 1992-06-19

Similar Documents

Publication Publication Date Title
SK62593A3 (en) Method of constructing synthetic leader sequences
JP3676369B2 (ja) 合成リーダーペプチド配列類
JP3542604B2 (ja) Ｙａｐ３シグナルペプチドをコードするｄｎａ構築体
JP3730255B2 (ja) イーストにおいて発現されたｎ末端に伸長した蛋白質
US4546082A (en) E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
IE892361L (en) Peptide and dna sequences
WO1989002463A1 (en) Synthetic yeast leader peptides
JPH06197787A (ja) 新規なるｄｎａ分子及び宿主
US4940661A (en) Metallothionein transcription control sequences and use thereof
JP4180112B2 (ja) 酵母細胞におけるｎ末端を伸長されたタンパクの発現のためのベクター
JP4668414B2 (ja) 形質転換した酵母細胞におけるタンパク質の製造方法
RU2167939C2 (ru) Способ продуцирования полипептида в дрожжах
CA2192942C (en) Synthetic leader peptide sequences
CZ20015A3 (cs) Rekombinantní exprimovaný kvasinkový vektor, způsob jeho získávání a transformovaná kvasinková buňka